Pacific Biosciences of California designs, develops and manufactures sequencing systems. Based on its Single Molecule, Real-Time sequencing technology, Co.'s products enable: de novo genome assembly to finish genomes in order to identify, annotate and decipher genomic structures; transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in gene families, and find genes; targeted sequencing to characterize genetic variations; and real-time kinetic information for epigenome characterization. The PacBio RS II, Sequel, Sequel II and Sequel IIe Systems conduct, monitor, and analyze biochemical sequencing reactions. The PACB stock yearly return is shown above.
The yearly return on the PACB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PACB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|